Small-molecule therapy for metastatic castration-resistant prostate cancer
转移性去势抵抗性前列腺癌的小分子治疗
基本信息
- 批准号:10325729
- 负责人:
- 金额:$ 100.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAnimalsAntineoplastic AgentsApoptosisBiological AssayBone TissueBusinessesCancer PatientCancer cell lineCanis familiarisCardiovascular systemCell LineCellsClinical PharmacologyClinical TrialsCollaborationsComplexCyclin D1Developmental Therapeutics ProgramDisseminated Malignant NeoplasmDoseDrug KineticsEZH2 geneEvolutionExcretory functionExhibitsF-Box ProteinsFormulationFutureGenerationsGeneticGrantGrowthHumanIn VitroInterventionInvestigational DrugsInvestigational New Drug ApplicationLeadMalignant NeoplasmsMalignant neoplasm of prostateMass Spectrum AnalysisMedicalMetabolismMetastatic Neoplasm to the BoneModalityModelingMolecular TargetMorbidity - disease rateNational Cancer InstituteOncogenicOncologyOralOrganOutcomePatient SelectionPatientsPharmaceutical PreparationsPharmacologyPhasePhosphotransferasesPilot ProjectsPre-Clinical ModelPrognosisPropertyProteinsProteomeQuality of lifeRelapseRodentRodent ModelRoleS PhaseSafetySamplingScheduleSignal TransductionSolidTechnology TransferTestingTherapeuticTissuesToxic effectToxicokineticsToxicologyTreatment EfficacyUnited StatesUrsidae FamilyXenograft ModelXenograft procedureabirateroneabsorptionandrogen deprivation therapybasebeta cateninc-myc Genescancer cellcastration resistant prostate cancerchemotherapyclinical developmentclinically relevantcytotoxicitydocetaxeldosagedrug candidatedrug developmentefficacious treatmentefficacy studyfollow-upgood laboratory practiceimprovedin vivoinhibitor/antagonistinnovationmortalitynanomolarnew therapeutic targetnovelpatient derived xenograft modelpre-clinicalpreclinical developmentpreclinical safetypreclinical studypreclinical toxicitypredictive markerprostate cancer cellrespiratoryskeletalsmall moleculesmall molecule inhibitorsubcutaneoussurvivinsurvivorshiptargeted treatmenttherapeutic targettherapy resistanttrial designtumortumor progressionubiquitin ligase
项目摘要
Metastatic, castration-resistant prostate cancer (mCRPC) is lethal with no cure. Although current treatments
initially prolong survival, patients generally relapse and develop therapeutic resistance, which is a major
obstacle in the management of prostate cancer. It is imperative to develop efficacious therapies to treat lethal
mCRPC and improve the survivorship of patients. During the Phase I STTR period, we identified a novel small-
molecule inhibitor of S phase kinase-associated protein 1 (Skp1) – F-Box protein (FBP) interaction, namely
GH501, that exhibits nanomolar potency against mCRPC and a broad spectrum of human cancer cell lines.
We have conducted pilot studies on the preclinical safety, pharmacokinetics, distribution and efficacy of GH501
against mCRPC. In this Phase II STTR project, we will test the central hypothesis that our lead compound
GH501 is a first-in-class Skp1-FBP inhibitor that effectively treats mCRPC. The proposed studies are built
upon: (1) an urgent and unmet medical need to develop new interventions for lethal mCRPC, (2) an imperative
need to identify new therapeutic targets in mCRPC; and (3) strong preclinical evidence supporting GH501 as a
novel and effective inhibitor of mCRPC. The overall objective is to conduct Investigational New Drug (IND)-
enabling toxicology and efficacy studies on GH501 as a drug candidate for the treatment of lethal mCRPC. In
Aim 1, we will develop an oral formulation of GH501 and test the hypothesis that GH501 has excellent safety
and drug-like properties in preclinical models. In Aim 2, we will validate the mechanism of action of GH501 and
test the hypothesis that as a novel Skp1 inhibitor, GH501 is efficacious against mCRPC in clinically-relevant
xenograft models. Completion of the proposed project and follow-up preclinical studies will allow us to prepare
an IND application within the next 3~4 years to advance GH501 into human trials. This highly innovative,
translational project could have a significant impact in reducing prostate cancer mortality and morbidity.
转移性、耐去势前列腺癌(MCRPC)是致命的,无法治愈。尽管目前的治疗方法
最初延长生存,患者通常会复发并产生治疗耐药性,这是一个主要的
前列腺癌治疗中的障碍。开发治疗致命疾病的有效疗法势在必行
MCRPC,提高患者的生存率。在第一阶段STTR期间,我们发现了一种新的小-
S时相激酶相关蛋白1-F-盒蛋白相互作用的分子抑制物,即
GH501,显示出对mCRPC和广泛的人类癌细胞系的纳摩尔效力。
我们已经对GH501的临床前安全性、药代动力学、分布和疗效进行了初步研究
针对mCRPC。在这个第二阶段的STTR项目中,我们将测试我们的先导化合物的中心假设
GH501是一种一流的Skp1-FBP抑制剂,能有效治疗mCRPC。建议的研究是建立的
关于:(1)迫切和未得到满足的医疗需要,以开发新的致命mCRPC干预措施,(2)当务之急
需要确定mCRPC的新治疗靶点;以及(3)强有力的临床前证据支持GH501作为一种
新型高效的mCRPC抑制剂。总体目标是进行新药研究-
使GH501作为治疗致死性mCRPC的候选药物的毒理学和疗效研究成为可能。在……里面
目的1,我们将开发一种GH501的口服制剂,并验证GH501具有极好的安全性的假设
以及临床前模型中的类药物特性。在目标2中,我们将验证GH501和
验证作为一种新的Skp1抑制剂,GH501在临床上对mCRPC有效的假设
异种移植模型。完成拟议的项目和后续的临床前研究将使我们能够准备
在未来3~4年内应用IND将GH501推进到人体试验中。这种高度创新的,
翻译项目可能会在降低前列腺癌死亡率和发病率方面产生重大影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAQING WU其他文献
DAQING WU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAQING WU', 18)}}的其他基金
Targeting chemoresistant prostate cancer with novel EED inhibitors
使用新型 EED 抑制剂靶向化疗耐药性前列腺癌
- 批准号:
10444602 - 财政年份:2022
- 资助金额:
$ 100.78万 - 项目类别:
Targeting chemoresistant prostate cancer with novel EED inhibitors
使用新型 EED 抑制剂靶向化疗耐药性前列腺癌
- 批准号:
10590661 - 财政年份:2022
- 资助金额:
$ 100.78万 - 项目类别:
Diversity Supplement: Targeting chemoresistant prostate cancer with novel EED inhibitors
多样性补充:用新型 EED 抑制剂靶向化疗耐药性前列腺癌
- 批准号:
10747516 - 财政年份:2022
- 资助金额:
$ 100.78万 - 项目类别:
Small-molecule therapy for metastatic castration-resistant prostate cancer
转移性去势抵抗性前列腺癌的小分子治疗
- 批准号:
10472020 - 财政年份:2017
- 资助金额:
$ 100.78万 - 项目类别:
Small-molecule therapy for metastatic prostate cancer
转移性前列腺癌的小分子治疗
- 批准号:
9407585 - 财政年份:2017
- 资助金额:
$ 100.78万 - 项目类别:
A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate Cancer
膳食补充剂作为去势抵抗性前列腺癌的辅助治疗
- 批准号:
8834755 - 财政年份:2015
- 资助金额:
$ 100.78万 - 项目类别:
EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis
EPLIN 作为金雀异黄素预防前列腺癌转移的分子靶点
- 批准号:
8854250 - 财政年份:2012
- 资助金额:
$ 100.78万 - 项目类别:
EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis
EPLIN 作为金雀异黄素预防前列腺癌转移的分子靶点
- 批准号:
8386046 - 财政年份:2012
- 资助金额:
$ 100.78万 - 项目类别:
EPLIN as a Molecular Target of Genistein in Preventing Prostate Cancer Metastasis
EPLIN 作为金雀异黄素预防前列腺癌转移的分子靶点
- 批准号:
8507638 - 财政年份:2012
- 资助金额:
$ 100.78万 - 项目类别:
Enhancement of Cancer Research at Clark Atlanta University
克拉克亚特兰大大学癌症研究的加强
- 批准号:
10376107 - 财政年份:1997
- 资助金额:
$ 100.78万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 100.78万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 100.78万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 100.78万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 100.78万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 100.78万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 100.78万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 100.78万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 100.78万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 100.78万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 100.78万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)